Search

Your search keyword '"Sparano, Joseph A"' showing total 1,405 results

Search Constraints

Start Over You searched for: Author "Sparano, Joseph A" Remove constraint Author: "Sparano, Joseph A"
1,405 results on '"Sparano, Joseph A"'

Search Results

53. Contributors

59. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

61. Supplementary Data Table 2 from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

62. Data from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

63. Supplementary Data Table 1 from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

67. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

68. Supplemental table 1 from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure

69. Table S1 from Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

70. Supplementary Table 1 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

72. Supplementary Figure 1 from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure

73. Supplementary Table S1 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

74. Supplementary Figure 1 from Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

75. Supplementary Figure Legends from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

76. Supplementary Figure 1 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

78. Supplementary Table 2 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

79. Supplementary Figure 2 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

80. Supplementary Tables 1 - 2 from Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial

81. Supplemental Table 1. from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

82. Supplementary Table 2 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

83. Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

86. Supplemental Table 2 from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

88. Data from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure

92. Supplementary Table 3 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

93. Supplementary Figure S2 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

96. Abstract OT1-11-01: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping

97. Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates

98. Abstract GS1-02: Racial disparity in tumor microenvironment and outcomes in residual breast cancer treated with neoadjuvant chemotherapy

Catalog

Books, media, physical & digital resources